Elevated pretreatment androgen levels correlate with significantly better overall survival in men with castration-resistant prostate cancer, regardless of treatment, a recent post hoc analysis of a large randomized trial showed.Charles BankheadAdvanstar Communications Inc...
Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study During the last years, there has been a rapid adoption of intensity-modulated radiation therapy (IMRT) in patients with prostate cancer (PCa), despite the ......
Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prosta- tectomy-a propensity scoring approach. J Urol. 2007;177:911-915.Tewari A, Divine G, Chang P, et al. Long-term survival in men with high grade ...
This cohort study examines the overall survival in men with very high-risk prostate cancer who are treated with radiotherapy and hormone therapy at
Prostate cancer (PCa) exhibits significant geoethnic disparities as reflected by distinct variations in the cancer genome and disease progression. Here, we perform a comprehensive proteogenomic characterization of localized high-risk PCa utilizing paired
In WHO Grade 2 carcinoma, the 5-year survival rate for patients with AgNOR/cell ≤ 7.84 was 77%, but was only 12% for those with higher counts (P < 0.0001). These survival rates were similar to those obtained when patients with WHO Grade 1 carcinoma and Grade 2 carcinoma plus l...
Cancer immunotherapies such as bispecific T-cell engagers have seen limited adoption in prostate cancer (PC), possibly due to differing levels of cancer receptor expression and effector T-cell infiltration between patients and inherent defects in T-cell engager design. Methods CD8+ T-cell infiltration...
Cancer 116, 5226–5234 (2010). Article PubMed Google Scholar Tewari, A. et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy—a propensity scoring approach. J. Urol. 177, 911–915 (2007)....
In patients with high-risk nonmetastatic prostate cancer treatment involving abiraterone acetate and prednisolone with or without enzalutamide added to androgen deprivation therapy for 2 years led to meaningfully enhanced survival outcomes. In patients with high-...
"The type of aggressive prostate cancer that we focused on has sometimes been regarded as so high risk that some patients even forgo local treatments like surgery or radiation because they are worried that the cancer has already spread and is incurable," said lead study author Amar Kishan, MD...